The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Early Increase of von Willebrand Factor Predicts Adverse Outcome in Unstable Coronary Artery Disease: Beneficial Effects of Enoxaparin
Open accessAbstract
Background —The pathogenesis of unstable angina and non–Q-wave myocardial infarction is still poorly understood, and early evaluation of prognosis remains difficult. We therefore studied the predictive value of 5 biological indicators of inflammation, thrombogenesis, vasoconstriction, and myocardial necrosis, and we examined the effects of enoxaparin and unfractionated heparin on these markers after 48 hours of treatment. Methods and Results —Sixty-eight patients with unstable angina or non–Q-wave myocardial infarction randomized in the international ESSENCE trial participated in this French substudy. C-reactive protein, fibrinogen, von Willebrand factor antigen, endothelin-1 and troponin I were measured on admission and 48 hours later. The composite end point of death, myocardial infarction, recurrent angina, or revascularization was significantly lower at 14 and 30 days of follow-up in patients allocated to enoxaparin compared with unfractionated heparin. All acute-phase reactant proteins were elevated on admission and increased further at 48 hours. Multivariate analysis demonstrated that the rise of von Willebrand factor over 48 hours was a significant and independent predictor of the composite end point at both 14 days and 30 days. Moreover the early increase of von Willebrand factor was more frequent and more severe with unfractionated heparin than with enoxaparin (mean change was +8.7±8.8% with enoxaparin versus +93.9±11.7% with unfractionated heparin, P <0.0001). The other clinical and biological variables did not predict outcome. Conclusions —In patients with unstable angina or non–Q-wave myocardial infarction, the acute-phase proteins increase over the first 2 days despite medical treatment. The early rise of von Willebrand factor is an independent predictor of adverse clinical outcome at 14 days and at 30 days. Enoxaparin provides protection as evidenced by the reduced release of von Willebrand factor, which represents a favorable prognostic finding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Antman, E. M., Tanasijevic, M. J., Thompson, B., Schactman, M., McCabe, C. H., Cannon, C. P., Fischer, G. A., Fung, A. Y., Thompson, C., Wybenga, D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610313351802 · Cited by 1,749
Cited by
Predicting Death in Patients With Acute Type A Aortic Dissection
Mehta, R. H., Suzuki, T., Hagan, P. G., Bossone, E., Gilon, D., Llovet, A., Maroto, L. C., Cooper, J. V., Smith, D. E., Armstrong, W. F., et al. (2002) · Circulation · doi:10.1161/hc0202.102246 · Cited by 581
Antman, E. M., Cohen, M., Radley, D., McCabe, C., Rush, J., Premmereur, J., & Braunwald, E. (1999) · Circulation · doi:10.1161/01.cir.100.15.1602 · Cited by 476
Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes
Spiel, A. O., Gilbert, J. C., & Jilma, B. (2008) · Circulation · doi:10.1161/circulationaha.107.722827 · Cited by 402
Circulating endothelial cells: Biomarker of vascular disease
Woywodt, A., Bertolini, F., Bull, T. M., Buyon, J. P., Clancy, R. M., Haubitz, M., Hebbel, R. P., Lip, G. Y. H., Mancuso, P., Sampol, J., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-09-0578 · Cited by 390
Circulating markers of inflammation and atherosclerosis
Lind, L. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00012-1 · Cited by 369
Metadata
- Authors
- Montalescot, G., Philippe, F., Ankri, A., Vicaut, E., Bearez, E., Poulard, J. E., Carrie, D., Flammang, D., Dutoit, A., Carayon, A., Jardel, C., Chevrot, M., Bastard, J. P., Bigonzi, F., & Thomas, D.
- Venue
- Circulation
- Published
- 1998-07-28
- Volume
- 98
- Issue
- 4
- Pages
- 294-299
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2064020544
- Cited by
- 250
- References
- 2
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.